Imbruvica, Gazyva combo meets in Phase III for first-line CLL

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib plus Gazyva obinutuzumab met the primary endpoint of improving progression-free survival (PFS) in the Phase III iLLUMINATE (PCYC-1130) trial to treat previously untreated chronic lymphocytic

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE